Background: We examined the prognostic value of a panel of biomarkers in patients with squamous cell carcinoma of the head and neck (SCCHN) who were human immunodeficiency virus (HIV) positive (HIV-positive head and neck cancer) and HIV negative (HIV-negative head and neck cancer).
| I NT ROD UCTI ON
The continued improvement and availability of highly active antiretroviral therapy (HAART) has dramatically prolonged survival in people living with human immunodeficiency virus (HIV) infection and AIDS. Although the incidence of AIDS-defining malignancies has declined in the post-HAART era, large epidemiological studies provide emerging evidence of increased risk of non-AIDSdefining cancers (non-AIDS-defining malignancies) over the past decade. 1, 2 The incidence of squamous cell carcinoma of the head and neck (SCCHN) is 4-fold higher in patients infected with HIV than in the general population. 3, 4 Smoking and alcohol consumption are known risk factors for the development of head and neck cancer 5, 6 in both patients who are HIV-positive and HIV-negative. 7 In addition, patients who are infected with HIV are susceptible to infection by oncogenic viruses, which may contribute to the higher rates of SCCHN. The risk of human papillomavirus (HPV)-associated SCCHN was found to be elevated among persons with AIDS and increased with increasing degrees of immunosuppression. 8, 9 Non-AIDS-defining malignancies, including oral cavity and pharyngeal cancer, are often associated with younger age at diagnosis of cancer and more aggressive and advanced stages of disease in the HIV-infected patient population than in the HIV-negative population. [10] [11] [12] Advanced cirrhosis and poorer outcome has been reported among patients infected with HIV with hepatocellular carcinoma 13 ; a higher risk of local recurrence and metastasis were also noted in patients infected with HIV with skin squamous cell carcinoma. 14 Poor survival in patients infected with HIV SCCHN is associated with low CD4 counts, a laryngeal/hypopharyngeal primary site and current tobacco use. 15 Thus, concerns over optimal treatment strategies and disease management arise when treating patients infected with HIV with SCCHN, especially smokers and alcohol users who have higher burden of comorbidity and possible coinfection with HPV. 16 The identification of prognostic factors in patients infected with HIV with SCCHN would be pivotal to the development of effective cancer prevention, surveillance, and treatment strategies. Hence, in this study, we examined protein expression of a panel of candidate prognostic biomarkers (nuclear factorkappa b [NF-jb], phosphorylated protein kinase B (pAKT) S473, pSTAT3Y705, B-cell lymphoma 2 (Bcl-2), transforming growth factor-beta [TGF-b] , interleukin [IL]-6, and vascular endothelial growth factor A [VEGF-A]), known to be associated with oncogenic activities, involved in the complex host-tumor interaction, or to function as inflammatory mediators, [17] [18] [19] [20] [21] acting either independently or in concerted fashion. Chronic inflammation affects all stages of cancer development 22 and signal transducer and activator of transcription 3 (STAT3), NF-jB, and IL-6 are key players in mediating the signaling pathways involved in inflammationinduced carcinogenesis, with the tissue microenvironment being the focal point of interaction between the tumor and host immune system. 23 Lung tumor growth in immunodeficient mice promoted by inflammation has been shown to be mediated by IL-6 through the STAT3/mitogen-activated protein kinase and NF-jB pathways, suggesting a strong causal link among immunodeficiency, inflammation, and cancer orchestrated by the STAT3 and NF-jB pathways. 24 Furthermore, immunosuppression can be worsened by proinflammatory factors induced by cigarette smoking 25, 26 in which process of the phosphotidylinositol-3-kinase/protein kinase B (AKT)/NF-jB pathway has been frequently implicated. 27 Like IL-6, TGF-b, an inflammatory cytokine and potent immune suppressor produced by cancer cells, myeloid cells, and T lymphocytes play a dual role in tumor suppression and promotion. 20 The Cancer Genome Atlas investigations in SCCHN have revealed that mutation profile and rates vary substantially by HPV infection, anatomic subsite, and smoking history, 28 which makes the identification of prognostic tumor biomarkers daunting. Thus, we conducted a retrospective study using tissue microarray (TMA) with tumor tissues derived from disease site-matched and age-matched patients with SCCHN who were HIV infected (HIV-positive head and neck cancer) and non-HIV-infected control patients (HIVnegative head and neck cancer). These rare specimens were acquired through the concerted effort of 5 Head and Neck Specialized Program of Research Excellence (HN-SPORE) centers. The purpose of this exploratory study was to examine the prognostic potential of candidate tumor biomarkers.
| P A TI ENT S A ND M ETHO DS

| Patients and tissue microarray construction
Patients were identified from 1 of 5 US tertiary care referral centers (Emory University, Johns Hopkins University, MD Anderson Cancer Center, University of Michigan, and University of Pittsburgh). The patients with HIV-positive head and neck cancer were diagnosed between 1991 and 2011; patients with HIV-negative head and neck cancer were diagnosed between 1996 and 2010. The study was approved by the institutional review boards of all participating institutions and was conducted using anonymized specimens.
The TMA was designed using tumor tissues derived from HIV-positive head and neck cancer cases and HIV-negative head and neck cancer controls with sufficient viable tumor tissues that allowed anatomic subsite and age matching.
Deidentified information, including demographic and clinical information, documentation of HIV infection, cancer diagnosis, behavior information, CD4 counts, viral load, and HAART use at the time of cancer diagnosis were submitted to the study data center as previously described. 15 Specimens were collected per recommended guidelines 29, 30 according to a well-defined protocol via collaboration of the head and neck cancer SPORE HIV consortium, and the TMA was centrally constructed and distributed by the University of Michigan. For each biomarker, 2 TMA slides (4-lm thickness) and 1 hematoxylin-eosin stained slide were obtained. Supporting Information Table S1 shows the number of cases used for each biomarker staining and the number of cases with clinical information. 15 The results of p16 staining were provided by investigators at the University of Michigan. The whole cell staining of all other biomarkers was assessed regardless of nuclear and/or cytoplasmic localization. Scoring was described previously 15 ; briefly, intensity of tumor cells staining: 1 5 no staining, 2 5 low, 3 5 moderate, and 4 5 high; proportion of tumor cells staining: 1: <5%, 2: 5%-20%, 3: 21%-50%, and 4: 51%-100%. The IHC scores (proportion times intensity) from each tissue core section were averaged for each patient. All specimens were scored by a boardcertified pathologist (G.S.) blinded to tumor categories.
| Immunohistochemistry
Tumor HPV DNA testing was conducted using PCR MassArray by investigators at the University of Michigan, as previously described, 15 all specimens with identified highrisk HPV types (HPV16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59, 66, 68, and 73) were scored as HPV-positive.
| Statistical analysis
Comparison between HIV-positive head and neck cancer cases and HIV-negative head and neck cancer control patients' characteristics and the correlation of IHC scores with clinical covariables were conducted using the t test or Wilcoxon ranksum test in which assumption of normal distribution was violated for numerical variables, and the chi-square test or Fisher's exact test for categorical variables. A logistic regression model was used to examine the adjusted association of each variable with HIV status after adjusting for other factors. Pairwise correlations between the 7 biomarkers were examined with Pearson or Spearman correlation coefficients. Univariate association of each biomarker with covariates was examined with the t test or Wilcoxon rank-sum test for categorical covariates, and Pearson correlation or Spearman correlation coefficient for numerical covariates, where appropriate.
Survival estimates were calculated for dichotomized biomarkers, binary prognostic factors, HIV status, and other categorical variables with the Kaplan-Meier method and compared between 2 stratified groups using the log-rank test. 31 Univariate and multivariable survival analyses were carried out using the Cox proportional hazards model. 32 The proportional hazards assumption was also examined with scaled Schoenfeld residuals. 33 To avoid choosing arbitrary cutoff points in the levels of biomarker expression, continuous variables were used in the model. Multivariable survival analysis was carried out by entering all variables in a Cox proportional hazard model and using a backward variable selection method with an alpha level of removal of 0.15, whereas the HIV variable was arbitrarily kept in the model. The HAART use at diagnosis and CD4 counts at cancer diagnosis were not included in the model as they were available only for patients with HIV-positive disease. January first of the year was used in which only the year of diagnosis or year of death/last contact was available. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC) and R package version 3.3.2 (The R Foundation for Statistical Computing) with 2-sided tests and a significance level of 0.05.
| R ES ULT S
| Patient characteristics
Forty-one cases with sufficient tumor tissues were identified from the original total of 71 patients with HIV-positive head and neck cancer who had HIV-related clinical information; 44 cases with sufficient anatomic subsite-matched and agematched tumor tissues were identified from the 47 HIVnegative head and neck cancer control patients. Patient characteristics are shown in Table 1 . We initially examined whether the subset used for the TMA study reflected the characteristics of the original HIV-positive head and neck cancer cohort 15 : the majority of the current subset were men (92.7%) versus 90.0% in the original cohort, 65.9% were on HAART at the time of cancer diagnosis (vs 80.3%), 19.5% had CD4 counts below 200 cells/lL (vs 26.8%), 65.9% were current alcohol users (vs 55.3%), and 19.5% were HPVpositive (vs 27.9% in the original cohort).
Eight of 41 HIV-positive head and neck cancer cases were HPV-positive as determined by HPV DNA testing (19.5%; 1 with HPV18 and 7 with HPV16); 5 of the oropharynx, 1 of the oral cavity, 1 of the larynx, and 1 of the parotid gland. Eight of 44 cases in the HIV-negative head and neck cancer group had HPV-positive disease (18%; 1 with HPV33 and 7 with HPV16); 5 were oropharyngeal, 2 were oral cavity, and 1 was laryngeal. Patients with HPV-positive disease were younger (48.3 6 9.1) than patients who were HPVnegative (52.8 6 10.3), although the difference was not significant (P 5 .11). The HIV-positive head and neck cancer group included 1 case of a parotid tumor, and the HIVnegative head and neck cancer group included 1 case of conjunctiva and 1 case of esophageal cancer.
Thirty-two of 41 patients (78.0%) with HIV-positive head and neck cancer had CD4 levels examined at the time of cancer diagnosis, 24 of these patients (75%) had CD4 counts 200 cells/lL. African Americans accounted for 71.4% of patients with low CD4 (<200 cells/lL). Within the HIV-positive group, 36 of 41 patients (87.8%) had HAART information available; 27 of these patients (75%) had taken HAART at the time of cancer diagnosis and 82.6% of the patients receiving HAART had high CD4 counts (200 cells/lL) compared with 57.1% of patients not taking HAART (P 5 .30; data not shown). The CD4 count was not correlated with stage at presentation, but interestingly, was significantly associated with disease site (P 5 .001); of the 8 patients with low CD4 counts (<200 cells/lL), 4 had laryngeal cancer (50%) compared with 13% (3/24) in patients with higher CD4 counts (200 cells/lL; data not shown).
When the HIV-positive head and neck cancer group was stratified by HPV status, patients with HPV-positive disease had significantly higher median CD4 counts (n 5 8; median 567; range 209-872) than HPV-negative patients (n 5 26; median 232; range 5-700; P 5 .04). Expression of biomarkers did not differ by CD4 level or by the use of HAART at cancer diagnosis.
| Correlations between biomarker expression, human immunodeficiency virus infection and prognostic factors
As the study groups were not matched based on race, there was a significantly greater proportion of African Americans (46.3%) in the HIV-infected group than in the HIV-negative group (6.8%; P < .001). The patients with HIV-positive head and neck cancer (N 5 41) were about 4.5 years younger than the patients with HIV-negative head and neck cancer (N 5 44; P 5 .04) and were more frequently current alcohol users (66% vs 23%; P < .001; Table 1 ). There was no significant difference in sex, tumor stage, disease site, HPV status, or smoking history between the HIV-positive head and neck cancer and HIV-negative head and neck cancer groups (Table 1 ). There was no significant difference in the expression of each of the 7 biomarkers (pAKT, NFjB, pSTAT3, Bcl-2, TGF-b, IL-6, and VEGF) between the HIV-positive head and neck cancer and the HIV-negative head and neck cancer groups (Supporting Information Table  S2 ). After stratifying by disease stage, VEGF expression levels were significantly lower in HIV-positive than HIVnegative stages I-II head and neck cancer (P 5 .01). The pSTAT3 expression levels were significantly lower in HIVpositive than HIV-negative stages III-IV disease (P 5.03; Table 2 ). We also examined the expression of biomarkers by HPV status. Levels of VEGF, IL-6, and NF-jB expression were significantly lower in HPV-positive head and neck cancer group than in the HPV-negative head and neck cancer group (P < .001, P 5 .04, and P 5 .01, respectively; Figure 1A) . The other 4 biomarkers (pAKT, pSTAT3, Bcl-2, and TGFb) were not associated with HPV status. The pAKT, NF-jB, and VEGF were expressed differentially by disease sites, with highest expression in the oral cavity (Table 3 ; P < .001, P < .001, and P 5 .02, respectively). Current alcohol use was strongly associated with HIV-positive status compared to former/never use (P < .001; Table 1 ), there was no interaction effect on the expression of any biomarker among HIV, HPV status, and alcohol use. Expression of pAKT was significantly lower in current alcohol users than in former or never users (Table 4 ; P 5 .02). White patients had higher pAKT expression than African American patients (P 5 .01; Table 4 ). The level of NF-jB was marginally significantly lower in African American than in white patients (P 5 .06).
| Correlations among biomarkers
To verify the signals detected by TMA, we examined the expression of key target molecules shared by the NF-jB and pSTAT3 pathways, including VEGF, IL-6, pAKT, and Bcl-2. 17 In both groups, marked associations were observed of pAKT with NF-jB (Supporting Information Table S3 ; P < .001 in both HIV-positive and HIV-negative head and neck cancer), NF-jB with VEGF (P 5 .02 in HIV-positive head and neck cancer; P < .001 in HIV-negative head and neck cancer), and TGF-b with IL-6 (P 5 .006 in HIV-positive head and neck cancer; P < .001 in HIV-negative head and neck cancer), whereas an inverse correlation of pSTAT3 with TGF-b was observed only in the HIV-positive head and neck cancer group (P < .05), and a correlation of Bcl-2 with pAKT, NF-jB, and TGF-b was observed only in the HIVnegative head and neck cancer group. When pAKT, pSTAT3, and NF-jB were grouped as an oncogenic signature using combined score, univariate association revealed that this signature was significantly associated with disease site (P < .001), former and current alcohol use (P 5 .04), and race (P 5 .02), but not with HIV status, HPV status, p16 positivity, age, sex, smoking history, CD4 count, or HAART use at cancer diagnosis (data not shown). Using a combined score of IL-6, VEGF, and TGF-b as a tumor microenvironment signature, this score was significantly lower in the HPV-positive group than in the HPV-negative group (P 5 .01).
| Prognostic value of biomarkers in overall survival
Survival data was available for 37 of 41 HIV-positive head and neck cancer cases (61.7%) and 23 of 44 HIV-negative head and neck cancer controls (38.3%). Median follow-up Abbreviations: Bcl-2, B-cell lymphoma 2; IL-6, interleukin; NF-jB, nuclear factor-kappa b; pAKT, phosphorylated protein kinase B; pSTAT3, phosphorylated signal transducer and activator of transcription 3; TGF-b, transforming growth factor-beta; VEGF, vascular endothelial growth factor. Data are presented as median (range). P value is calculated by Wilcoxon rank-sum test. a These cases were not included in the analysis due to different histology origin: 1 case of parotid gland in the HIV-positive head and neck cancer group; 1 case of esophageal and 1 case of conjunctiva in the HIV-negative head and neck cancer group.
F IGUR E 1 A, Expression of 7 biomarkers by human papillomavirus (HPV) status presented as a boxplot. Expression levels of interleukin (IL)-6, nuclear factor-kappa b (NFjB), and vascular endothelial growth factor (VEGF) were significantly lower in the HPV-positive group than in the HPVnegative group. B, Kaplan-Meier estimates for all patient cohorts by human immunodeficiency virus (HIV) status. Overall survival did not differ among the patients in the HIV-positive head and neck cancer group and the HIV-negative head and neck cancer group. Bcl-2, B-cell lymphoma 2; pAKT, phosphorylated protein kinase B; pSTAT, phosphorylated signal transducer and activator of transcription; TGFb, transforming growth factor-beta was 565 days for the HIV-positive head and neck cancer cases and 1095 days for the HIV-negative head and neck cancer controls. Survival analysis was conducted for all groups in which both biomarker and survival information were available. When only the HIV-positive head and neck cancer cases with all clinical covariables were considered, univariate analysis showed that laryngeal disease site (P 5.003) and CD4 count <200 cells/lL (P 5 .01) were associated with poor prognosis of overall survival (OS), whereas HPV coinfection did not have a significant impact on OS (Supporting Information Table S4 ). As expected, the HIVnegative head and neck cancer group exhibited typically poor prognosis associated with advanced age and stage (Supporting Information Table S5 ). Multivariate analysis with all biomarkers and clinical covariables in all patient groups is summarized in Table 5 . The best predictive survival model using a Cox proportional hazard model included HIV infection, p16, pAKT, IL-6, and TGF-b. In the best predictive model, HIV infection and p16 were treated as binary variables, whereas pAKT, IL-6, and TGF-b were treated as continuous variables. The HIV status did not have a significant impact on OS in all patient groups after adjusting for the significant biomarkers in the best predictive model ( Figure 1B) . Improved OS was associated with positive p16 (P < .001) 
| D IS C US S I ON
To our knowledge this is the first multi-institutional study exploring the prognostic significance of a panel of tumor biomarkers among patients with HIV-positive head and neck cancer and HIV-negative head and neck cancer. To reduce bias, comparison between groups was conducted by pairing each tumor specimen based on anatomic site and patient's age whenever possible. We chose a panel of oncogenic (NF-jB, pAKT, pSTAT3, and Bcl-2) and inflammatory (TGF-b, IL-6, and VEGF) tumor biomarkers known to play roles independently or cooperatively in tumor growth and progression and tumor-host immune interaction.
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The subset of patients with HIV-positive head and neck cancer largely retained the characteristics of the original patient cohort, particularly, consistent with the findings in the original study, 15 we found that low CD4 count (<200 cells/lL) was significantly associated with poor OS in the HIV-positive head and neck cancer cases when only clinical information was included (Supporting Information Table  S4) . 34 In addition, current alcohol users were more likely to have HIV infection compared with nonalcohol or former alcohol users (OR 6.0; 95% CI 1.8-20.0; P 5 .003), consistent with the high prevalence of lifestyle-related cancer risk factors (smoking and alcohol intake) associated non-AIDS-defining malignancies among patients with HIV infection. 7, 35, 36 The cases of HIV infection did not have significant impact on patients' OS, consistent with the findings of investigators who used specimens derived from similar cohorts. 34 Our study has revealed that TGF-b expression stands out as an independent poor prognosis factor for OS, a better prognostic factor than stage, disease site, HIV, and/or HPV infection when controlling for all clinical covariables and the expression levels of the other biomarkers in all patient groups ( Table 2 ). The TGF-b, an inflammatory cytokine and potent immune suppressor, plays a dual role in cancer development by acting as a tumor suppressor during the early stages and as a tumor promoter during the later stages of disease. 20 One of the mechanisms by which tumor TGF-b may promote tumorigenesis is through acting as a potent immunosuppressor, and/or recruiting regulatory T cells (CD25 6 Foxp3) and myeloid-derived suppressor cells, 19 thus decreasing tumor cell recognition and clearing by the innate immune system. In a recent randomized phase II trial of cetuximab with or without sorafenib in recurrent and/or metastatic SCCHN, high plasma TGF-b was found to be associated with inferior progression-free survival regardless of the study arm. 37 Furthermore, patients with SCCHN receiving singleagent cetuximab had increased frequency of CD41FOXP31 intratumoral recruiting regulatory T cells expressing CTLA-4, CD39, and TGF-b, which were associated with suppressed cetuximab-mediated antibody-dependent cellular cytotoxicity and poor clinical outcomes. 38 These studies underscore the complexity of proinflammatory tumor markers and demand more systematic future approaches to study tumor biomarkers, including host immune status, tumor infiltrating cells, and genomic approaches to identify molecular signatures with prognostic value. In addition to TGF-b being detected as a significant negative prognostic factor, multivariate analysis detected a statistically significant effect of p16 positivity and increased pAKT and IL-6 expression on OS. The strong prognostic effect of positive p16 on superior clinical outcome was detected in all patient groups, including oral cavity, laryngeal, and oropharyngeal disease site. Our findings are consistent with those of a study assessing the prognostic effect of positive p16 by IHC in oral cavity, hypopharyngeal, and laryngeal cancers. 39 It has been reported that elevated systemic IL-6 level at baseline was strongly related with all-cause mortality in patients infected with HIV 40 and at 1 year post-HAART treatment with non-AIDS-defining events. 41 It remains to be examined whether the levels of host systemic IL-6 and tumor IL-6 convey similar or different profiles regarding host immune status. The slightly beneficial effect of both pAKT and IL-6 expression on OS indicated by the odd ratios (Table 5) warrants further investigation. Evidence of a differential effect of HPV on tumor biomarkers in SCCHN has begun to emerge. 42 The current study observed lower expression levels of IL-6, VEGF, and NF-jB in the HPV-positive head and neck cancer group than in the HPV-negative head and neck cancer group (Figure 1A) , furthermore, the strong association of VEGF with NF-jB was not affected by HIV infection (Supporting Information Table S3 ). A recent biomarker study of head and neck cancer tissues from the base of tongue, tonsils, and vocal fold revealed that tumor IL-6 assessed by IHC and serum IL-6 were significantly lower in patients with HPV16-positive disease (N 5 11) than in HPV-negative patients (N 5 11), but IL-6 expression levels were not correlated with SCCHN location, stage, or level of HPV viral load. 43 A study of hypoxia-related genes in oropharyngeal squamous cell carcinoma found that HPV-positive tumors displayed less hypoxia than HPV-negative tumors. 44 A study using high-throughput analyses and the TRANScription FACtor (TRANSFAC) database reported that HPV-positive tumors had reduced whole cell protein expression and significantly lower nuclear staining of both STAT3 and NF-jB by IHC than HPV-negative tumors, marked colocalization, and coactivation of both transcription factors was observed by TMA. 45 Taken together, our findings are consistent with the consensus that HPV infection has significant effects on the tumor expression of IL-6, VEGF, and NF-jB. We were surprised by a more prominent effect of disease anatomic site (Table 3) , race, and alcohol use (Table 4) than HIV infection and CD4 counts on biomarker expression. This is consistent with the notion of distinct molecular signatures according to disease anatomic site and the impact of risk behaviors, such as cigarette smoking on tumor genetic characteristics identified by the Cancer Genome Atlas investigations. 28 The lack of significant effect of HIV infection raises further questions, such as whether a patient's viral load may be a better prognostic factor than HIV infection for disease progression and OS, whether HIV infection alone or HPV coinfection may have significant effect on tumor biomarker expression, and whether the anatomic site and/or risk behaviors may have greater impact than HIV infection on tumor molecular characteristics and behaviors. Whether these factors are related to the strong association of the prevalence of HIVpositive head and neck cancer with race, sex, age, CD4 counts, and risk behaviors 1,2,12 certainly warrants further investigation.
The limitations of this study include the retrospective and observational nature of the design, limited sample size, missing information of stage and viral load, single pathologist review, and the lack of information on detailed treatment history and progression-free survival, which is highly relevant to disease progression.
In summary, tumor biomarkers were not differentially regulated by HIV status and HIV infection did not have significant impact on OS of patients with head and neck cancer. The high expression of TGF-b was significantly associated with poor OS, whereas positive p16 status was significantly associated with improved OS. Addition of biomarkers, such as TGF-b, to the conventional risk stratification equation could improve prognostic and predictive values, and it would be desirable to implement a disease management strategy targeting this growing but largely underinvestigated patient population. 
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